standard statistics were used with a p value of <0.05 considered significant. RESULTS: There were 314 women identified, 178 (56.7%) with methadone use and 136 (43.3%) with buprenorphine use. Both groups were similar in maternal age, race, parity, homeless rate, tobacco use, mode of delivery and incidence of neonatal abstinence syndrome (NAS) OBJECTIVE: To explore the effects of gestational OMT on placental development STUDY DESIGN: This is a retrospective cohort study of pregnant patients on OMT (buprenorphine or methadone) between January 2007 and December 2017. ICD codes were used to identify OMT patients. The control group consisted of random non-drug users matched for GA. Patients were excluded if they had gestational diabetes, multiple gestations, positive meconium toxicology results for substances other than methadone or buprenorphine and those without microscopic placental evaluation. Placental weight and histologic evaluation were obtained and compared among the groups. Data analysis was performed using one-way ANOVA with pvalue <0.05 significant. RESULTS: 454 cases were reviewed; of which 109 met the inclusion criteria (66 patients were on methadone, 43 were on buprenorphine, and 40 were controls). Gestational age at birth and neonatal birth weight were significantly lower in the methadone group compared to the buprenorphine and control groups . The placenta to neonatal birth weight ratio was significantly higher in the methadone and buprenorphine groups compared to controls (p<0.01). There was no statistically significant difference between methadone and buprenorphine groups (mean AE standard deviation; methadone: 0.19 AE 0.03; buprenorphine: 0.18 AE 0.04; control: 0.15 AE 0.03).The rate ratio of placental dysmaturity (Figure 1 ) was significantly higher in the methadone and buprenorphine groups compared to control (rate ratio 3.8 and 3.7) CONCLUSION: Gestational OMT is associated with placentomegaly and placental dysmaturity compared to non-drug users. These findings are correlated with reduced surface area for oxygen diffusion, which may affect neonatal well-being. Further analysis is underway to evaluate the effects of placental dysmaturity on neonatal outcomes. OBJECTIVE: Neonates exposed to opioids in utero present a growing public health crisis in the US as the incidence of neonatal opioid withdrawal (NOW) has nearly tripled in the last two decades. Treatment of NOW can vary among hospitals thereby making it difficult to identify the most effective approach. Non-pharmacological management, such as parental presence, rooming-in, and breastfeeding, have been shown to decrease the severity of withdrawal. Studies suggest that infants with NOW who require pharmacologic treatment have lower cognitive scores. The objective of this study was to determine the optimal management strategy of NOW and its effects on neurodevelopmental outcomes.
314 Is opioid maintenance therapy (OMT) associated with placentomegaly and placental dysmaturity?
Cara Staszewski, Elizabeth Kertowidjojo, Victoria Ly, Diana Garretto, Cynthia Kaplan, David Garry, Malini Persad, Kimberly Herrera Stony Brook University Hospital, Stony Brook, NY OBJECTIVE: To explore the effects of gestational OMT on placental development STUDY DESIGN: This is a retrospective cohort study of pregnant patients on OMT (buprenorphine or methadone) between January 2007 and December 2017. ICD codes were used to identify OMT patients. The control group consisted of random non-drug users matched for GA. Patients were excluded if they had gestational diabetes, multiple gestations, positive meconium toxicology results for substances other than methadone or buprenorphine and those without microscopic placental evaluation. Placental weight and histologic evaluation were obtained and compared among the groups. Data analysis was performed using one-way ANOVA with pvalue <0.05 significant. RESULTS: 454 cases were reviewed; of which 109 met the inclusion criteria (66 patients were on methadone, 43 were on buprenorphine, and 40 were controls). Gestational age at birth and neonatal birth weight were significantly lower in the methadone group compared to the buprenorphine and control groups . The placenta to neonatal birth weight ratio was significantly higher in the methadone and buprenorphine groups compared to controls (p<0.01). There was no statistically significant difference between methadone and buprenorphine groups (mean AE standard deviation; methadone: 0.19 AE 0.03; buprenorphine: 0.18 AE 0.04; control: 0.15 AE 0.03).The rate ratio of placental dysmaturity (Figure 1 ) was significantly higher in the methadone and buprenorphine groups compared to control (rate ratio 3.8 and 3.7) CONCLUSION: Gestational OMT is associated with placentomegaly and placental dysmaturity compared to non-drug users. These findings are correlated with reduced surface area for oxygen diffusion, which may affect neonatal well-being. Further analysis is underway to evaluate the effects of placental dysmaturity on neonatal outcomes. OBJECTIVE: Neonates exposed to opioids in utero present a growing public health crisis in the US as the incidence of neonatal opioid withdrawal (NOW) has nearly tripled in the last two decades. Treatment of NOW can vary among hospitals thereby making it difficult to identify the most effective approach. Non-pharmacological management, such as parental presence, rooming-in, and breastfeeding, have been shown to decrease the severity of withdrawal. Studies suggest that infants with NOW who require pharmacologic treatment have lower cognitive scores. The objective of this study was to determine the optimal management strategy of NOW and its effects on neurodevelopmental outcomes.
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